Mallinckrodt plc, global specialty biopharmaceutical company, will enhance commercial capabilities to realize the potential of the organization's hospital and autoimmune and rare diseases (ARD) businesses and redouble its focus on portfolio expansion. The company will amplify its focus on business strategy and portfolio development and intensify efforts to expand and deepen talent in its commercial organization.
To that end, the company will create a new cohort of general business manager roles across the organization with four in key ARD therapeutic areas (rheumatology, neurology, nephrology, and pulmonology) and similar leadership roles in Mallinckrodt's Hospital and Office Brands franchises. Internal candidates are being reviewed and external market searches are also underway.
With the company's focus on rapid expansion of the core business accelerated through partnership and acquisitions, Dr. Gary Phillips has been asked to resume his previous role as Mallinckrodt's senior vice president, chief strategy officer, heading up strategy and business development and licensing efforts across the entire portfolio.
As the business continues efforts to build out its broader commercial organization, Hugh O'Neill, senior vice president and president, specialty pharmaceuticals, will assume responsibility for all specialty pharmaceutical commercial operations, including the hospital organization which he currently oversees and, in the interim, the sales, support and service activities for the recently acquired ARD business. O'Neill will also continue to have responsibility for the company's broad market access activities.
Mr. Phillips and Mr. O'Neill will continue to serve as members of Mallinckrodt's Executive Committee, and report directly to Mark Trudeau, president and chief executive officer of Mallinckrodt. Both executives' appointments were effective January 7, 2015.